Product Details
Product Name:
ABT-724 |
CAS No.:
70006-24-5 |
Purity:
99.73% |
Supply Ability:
10g |
Release date:
2025/07/23 |
Product Introduction
Bioactivity
Name | ABT-724 |
Description | ABT-724 is an agonist of dopamine D4 receptor(EC50: 12.4 nM) |
Animal Research | ABT-724 (maleate salt) was freshly prepared and administered to rats via s.c. injection into the back neck area (1 ml/kg injection volume). For intracerebroventricular (ICV) or intrathecal administrations, rats were allowed at least 1 week of recovery from surgery before behavioral testing. The compounds of interest were infused ICV (left lateral ventricle) in a 5-μl volume or 10 μl intrathecally. After the experiment was completed, infusion of 0.5% fast-green dye in saline solution and subsequent dissection were carried out to confirm the diffusion of the injection solution[1]. |
In vitro | ABT-724 is a selective dopamine D(4) receptor agonist that activates human dopamine D(4) receptors with an EC(50) of 12.4 nM and 61% efficacy, with no effect on dopamine D(1), D(2), D(3), or D(5) receptors[1]. |
In vivo | ABT-724 dose-dependently facilitates penile erection when given s.c. to conscious rats, an effect that is blocked by haloperidol and clozapine but not by domperidone.?A proerectile effect is observed after intracerebroventricular but not intrathecal administration, suggesting a supraspinal site of action.?s.c. injections of ABT-724 increase intracavernosal pressure in awake freely moving rats.?In the presence of sildenafil, a potentiation of the proerectile effect of ABT-724 is observed in conscious rats.?The ability of ABT-724 to facilitate penile erection together with the favorable side-effect profile indicates that ABT-724 could be useful for the treatment of erectile dysfunction[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Solubility Information | DMSO : 10 mg/mL (34.09 mM), Sonication is recommended.
|
Keywords | potentiation,side-effect | penile | Inhibitor | inhibit | erection | DopamineReceptor | Dopamine Receptor | Dopamine | D4-receptor | D4 | ABT-724 | ABT724 | ABT 724 |
Inhibitors Related | Olanzapine | Clozapine N-Oxide | Mirtazapine | Octopamine hydrochloride | Benserazide hydrochloride | L-DOPA | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:189498-57-5
$50.00 / 5mg
-
CAS:1422253-38-0
$42.00 / 1mg
-
CAS:587870-77-7
$34.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-30 |
|
$10.00/1ASSAYS |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-05-04 |
|
$0.00/1kg |
VIP2Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2024-01-19 |